Pathogenetic Aspects of Myelodysplastic Syndromes

References

• Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Grainick, H. R. and Sultan, C. (1982). Proposals for the classification of the myelodysplastic syndromes, Br. J. Haematol., 51, 189–199.
   PubMed Web of Science ®Google Scholar
• Hamblin, T. and Oscier, D. G. (1987). The myelodysplastic syndromes a practical guide, Haematological Oncology, 5, 19.
   PubMed Web of Science ®Google Scholar
• Aul, C., Gattermann, N. and Schneider, W. (1995). Epidemiological and etiological aspects of myelodysplastic syndromes, Leukaemia and Lymphoma, 16, 247–262.
   PubMed Web of Science ®Google Scholar
• Aul, C., Germing, U. and Gattermann, N. (1997). Increasing incidence of MDS: Real or fictitious?, Leukaemia Research, Vol. 21, Supp. 1, S3(10).
   PubMedGoogle Scholar
• West, R. R., Stafford, D. A., Farrow, A. and Jacobs, A. (1995). Occupational and environmental exposures and myelodysplasia: a case-control study, Leukaemia Research, 19, 127–139.
   PubMed Web of Science ®Google Scholar
• Nisse, C., Grandbastien, B., Brizard, A., Hebbar, M., Haguenoer, J. M. and Fenaux, P. (1997). Occupational and environmental risk factors of MDS: a case control study, Leukaemia Research, Vol. 21, Supp.l, S4(15).
   Web of Science ®Google Scholar
• Hayes, R. B., Yin, S.-N., Dosemeci, M., Li, G.-L., Wacholder, S., Travis, L. B., Li, C.-Y., Rothman, N., Hoover, R. N. and Linet, M. S. (1997). Benzene and dose-related incidence of hematologic neoplasms in China, Journal of the National Cancer Institute, 89(14), 1065–1071.
   PubMed Web of Science ®Google Scholar
• Smith, M. T., Rothman, N., Yin, S.-N., Zhang, L., Dosemeci, M., Wang, Y., Li, G.-L. and Hayes, R. B. (1997). Benzene exposure and risk of MDS/AML, Leukaemia Research, Vol. 21, Supp. 1, S3(9).
   Google Scholar
• Chen, H., Sandler, D. P., Taylor, J. A., Shore, D. L., Liu, E. and Bloomfield, C. D. (1996). Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defects, Lancet, 347(8997), 295–297.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Nisse, C., Hebbar, M., Vanrumbeke, M., Brizard, A., Lai, J. L. and Fenaux, P. (1997). Glutathione S Transferase Theta 1 (GSTT1) gene defects in myelodysplastic syndromes (MDS) and their correlation with karyotype and exposure to potential carcinogens, Leukaemia Research, Vol. 21, Supp. 1, S3(11).
   Google Scholar
• Pedersen-Bjergaard, J., Specht, L., Larsen, S. O. et al. (1987). Risk of therapy related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents and time from chemotherapy, Lancet ii, pp. 83–88.
   Google Scholar
• Tucker, M. A., Coleman, C. N., Cox, R. S. et al. (1988). Risk of second cancers after treatment for Hodgkin's disease, New England Journal of Medicine, 318, 76–81.
   PubMed Web of Science ®Google Scholar
• Kaldor, J. M., Day, N. E., Clarke, A. et al. (1990). Leukaemia following Hodgkin's disease, New England Journal of Medicine, 322, 7–13.
   PubMed Web of Science ®Google Scholar
• Pui, C. H., Hanckock, M. L., Raimonds, S. C. et al. (1990). Myeloid neoplasia in children treated for solid tumours, Lancet, 336, 417–421.
   PubMed Web of Science ®Google Scholar
• Lavey, R. S., Eby, N. L. and Prosnitz, L. R. (1990). Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas, Cancer, 66, 80–88.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard, J., Ersbol, J., Sorenson, H. M. et al. (1985). Risk of acute non-lymphocytic leukaemia and preleukaemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma, Annals of Internal Medicine, 103, 195–200.
   PubMed Web of Science ®Google Scholar
• Greene, M. H., Young, R. C., Merril, J. M. et al. (1983). Evidence of treatment dose response in acute non lymphocytic leukaemia which occur after therapy of non-Hodgkin's lymphoma, Cancer Research, 43, 1891–1898.
   PubMed Web of Science ®Google Scholar
• Ingram, L., Mott, M. G., Mann, J. R. et al. (1987). Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia in the UKCCSG regimens, British Journal of Cancer, 55, 463–466.
   PubMed Web of Science ®Google Scholar
• Bergsagel, D. E., Bailey, A. J., Langley, G. R. et al. (1979). The chemotherapy of plasma cell myeloma and the incidence of acute leukaemia, New England Journal of Medicine, 301, 743–748.
   PubMed Web of Science ®Google Scholar
• Cuzic, J., Erskine, S., Edelman, D. et al. (1987). A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis, British Journal of Cancer, 55, 523–529.
   PubMed Web of Science ®Google Scholar
• Pui, C. H., Ribeiro, R. C., Hancock, M. L. et al. (1991). Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia, New England Journal of Medicine, 325, 1682–1687.
   PubMed Web of Science ®Google Scholar
• Winick, N., McKenna, R. W., Shuster, J. J. et al. (1993). Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide, Journal of Clinical Oncology, 2, 209–217.
   Google Scholar
• Orchard, J. A., Bolan, S., Oscier, D. G. (1998). Association of myelodysplastic changes with purine analogues, British Journal of Haematology, 100, 677–679.
   PubMed Web of Science ®Google Scholar
• Kouides, P. A. and Bennet, J. M. (1992). Morphology and classification of myelodysplastic syndromes. In: Haematology/Oncology clinics of North America, Myelodysplastic Syndromes, (Guest Ed.) Koeffler, H. P., 6, 485–99.
   Google Scholar
• Mufti, G. J., Stevens, J. R., Oscier et al. (1985). Myelodysplastic syndromes: a scoring system with prognostic significance, British Journal of Haematology, 59, 425.
   PubMed Web of Science ®Google Scholar
• Goasguen, J. E., Garand, R., Bizet, M. et al. (1990). Prognostic factors of myelodysplastic syndromes-a simplified 3-D scoring system, Leukaemia Research, 14, 255.
   PubMed Web of Science ®Google Scholar
• Third MIC cooperative study Group. (1988). Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy related myelodysplastic disorders, Cancer Genetics Cytogenetics, 32, 1.
   PubMed Web of Science ®Google Scholar
• Sanz, G. F., Sanz, M. A., Vallepspi, T. et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients, Blood, 74, 395.
   PubMed Web of Science ®Google Scholar
• Goasguen, J. E., Bennet, J. M., Cox et al. (1989). Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome, Leukaemia Research, 15, 159–165.
   Web of Science ®Google Scholar
• Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M. et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079.
   PubMed Web of Science ®Google Scholar
• Pagliuca, A., Layton, D. M., Manoharan, A. et al. (1989). Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases, British Journal of Haematology, 71, 499–504.
   PubMed Web of Science ®Google Scholar
• Tricot, G., De Wolf-Peeters, C., Vlientinck, R. et al. (1984). Bone marrow histology in myelodysplastic syndromes II. Prognostic value of abnormal localization of immature precursors in MDS, British Journal of Haematology, 58, 217–225.
   PubMed Web of Science ®Google Scholar
• Mangi, M. H. and Mufti, G. J. (1992). Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies, Blood, 79, 198–205.
   PubMed Web of Science ®Google Scholar
• Mangi, M. H., Salisbury, J. R. and Mufti, G. J. (1991). Abnormal localisation of immature precursors (ALIP) in the bone marrow of myelodysplastic syndromes: Current state of knowledge and future directions, Leukaemia Research, 15, 627–639.
   PubMed Web of Science ®Google Scholar
• Van den Berghe, H., Cassiman, J. and David, G. (1974). Distinct haematological Disorder with deletion of the long arm of No. 5 chromosome, Nature, 251, 437–438.
   PubMed Web of Science ®Google Scholar
• Van den Berghe, H., Vermaden, K., Mecucci, C. et al. (1985). The 5q-anomaly, Cancer Genetics Cytogenetics, 17, 189–255.
   PubMed Web of Science ®Google Scholar
• Yunis, J. J., Rydell, R. E., Oken, M. M. et al. (1986). Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes, Blood, 66, 1721–1730.
   Google Scholar
• Lai, J. L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Lepelley, P., Wattel, E. and Fenaux, P. (1995). Myelodysplastic syndromes and acute myeloid leukaemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations, Leukaemia, 9, 370–381.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Lai, J. L., Soenen, C., Roumier, V. and Fenaux, P. (1997). Morphological, cytogenetic, molecular and etiological features of the “17p syndrome” in MDS, Leukaemia Research, Vol.21, Supp. 1, S29 (113).
   Google Scholar
• Juneja, S. K., Imbert, M., Sigaux, S. et al. (1983). Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes, Journal of Clinical Pathology, 36, 566–567.
   PubMed Web of Science ®Google Scholar
• May, A., De Souza, P., Barnes, K. et al. (1982). Erythroblast iron metabolism in sideroblastic marrows, British Journal of Haematology, 52, 611–621.
   PubMed Web of Science ®Google Scholar
• Gattermann, N., Aul, C. and Schneider, W. (1990). Two types of acquired idiopathic sideroblastic anaemia (AISA), British Journal of Haematology, 74, 45–52.
   PubMed Web of Science ®Google Scholar
• Bowen, D. and Jacobs, A. (1989). Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects, Journal of Clinical Pathology, 42, 56–58.
   PubMed Web of Science ®Google Scholar
• Cotter, P. D., Baumann, M. and Bishop, D. F. (1992). Enzymatic defect in “X-linked” sideroblastic anaemia: molecular evidence for erythroid δ-aminolevulinate synthase deficiency, Proceedings of the National Academy of Science USA, 89, 4028–4032.
   PubMed Web of Science ®Google Scholar
• Cox, T. C., Bottomley, S. S., Wiley, J. S., Bawden, M. J., Mathews, C. S. and May, B. K. (1994). X-linked pyridoxine- responsive sideroblastic anaemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase, New England Journal of Medicine, 330, 675–679.
   PubMed Web of Science ®Google Scholar
• Cotter, P. D., May, A., Fitzsimons, E. J., Houston, T., Woodcock, B. E., Al-Sabah, A. I., Wong, L. and Bishop, D. F. (1995). Late-onset X-linked sideroblastic anaemia. Missense mutations in the erythroid δ-aminolevulinate synthase (ALAS2) gene in two pyridoxine responsive patients initially diagnosed with acquired refractory anaemia and ringed sideroblasts, Journal of Clinical Investigation, 96, 2090–2096.
   PubMedGoogle Scholar
• Gattermann, N., Retzlaff, S., Wang, Y.-L., Berneburg, M., Heinisch, J., Wlaschek, M., Aul, C. and Schneider, W. (1996). A heteroplasmic point mutation of mitochondrial tRNALeu (CUN) in non-lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia, British Journal of Haematology, 93, 845–855.
   PubMed Web of Science ®Google Scholar
• Gatterman, N., Retzlaff, S., Wang, Y.-L., Aul, C. and Schneider, W. (1997). Heteroplasmic point mutations of mitochondrial DNA affecting subunit 1 of cytochrome C oxidase in two patients with acquired idiopathic sideroblastic anaemia, Leukaemia Research, Vol. 21, Supp. 1, S36(139).
   Google Scholar
• Jacobs, A. (1987). Human leukaemia, do we have a model?, British Journal of Cancer, 55, 1–5.
   PubMed Web of Science ®Google Scholar
• Hamblin, T., Culligan, D. J., Jacobs, A. et al. (1991). Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice, Leukaemia Research, 16, 3–11.
   Web of Science ®Google Scholar
• Second International Workshop on chromosomes in leukaemia (1979). Chromosomes in preleukaemia, Cancer Genetics Cytogenetics, 2, 108–113.
   Google Scholar
• Nowel, P. C. (1982). Cytogenetics of preleukaemia, Cancer Genetics Cytogenetics, 5, 265–278.
   PubMedGoogle Scholar
• Nowel, P. C. and Besca, E. C. (1989). Prognostic significance of single chromosome abnormalities in preleukaemic states, Cancer Genetics Cytogenetics, 42, 1–7.
   PubMedGoogle Scholar
• Yunis, J. J., Rydell, R. E., Oken, M. M. et al. (1986). Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes, Blood, 67, 1721–1730.
   PubMed Web of Science ®Google Scholar
• Geddes, A. D., Bowen, D. T. and Jacobs, A. (1990). Clonal Karyotypic abnormalities and clinical progress in the myelodysplastic syndromes, British Journal of Haematology, 76, 194–202.
   PubMed Web of Science ®Google Scholar
• White, A. D., Culligan, D. J. and Jacobs, A. (1992). Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS), British Journal of Haematology, 81, 499–502.
   PubMed Web of Science ®Google Scholar
• White, A. D., Hoy, T. G. and Jacobs, A. (1994). Extended cytogenetic follow up and clinical progress in patients with myelodysplastic syndromes (MDS), Leukaemia and Lymphoma, 12(5–6), 401–412.
   PubMed Web of Science ®Google Scholar
• Yunis, J. J., Lobell, M., Arnesen, M. A. et al. (1988). Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelodysplastic syndrome and acute myelogenous leukaemia, British Journal of Haematology, 68, 189–194.
   PubMed Web of Science ®Google Scholar
• Bloomfield, C. D. (1986). Chromosomal abnormalities in secondary myelodysplastic syndromes, Scandanavian Journal of haematology, 45, Supp. 82.
   Google Scholar
• Pedersen-Bjergaard, J., Philip, P., Larsen, S. D. et al. (1990). Chromosome aberrations and prognostic factors in therapy related MDS and acute non-lymphocytic leukaemia, Blood, 76, 1087–1091.
   Web of Science ®Google Scholar
• Le Beau, M. M., Albain, K. S., Larson, R. A. et al. (1986). Clinical and cytogenetic correlation in 63 patients with therapy related myelodysplastic syndromes and acute non-lymphocytic leukaemia, Further evidence for characteristic abnormalities of chromosome 5 and 7, Journal of Clinical Oncology, 4, 325–345.
   PubMed Web of Science ®Google Scholar
• Iurlo, A., Mecucci, C., Van Orshoven, A. et al. (1989). Cytogenetic and clinical investigations in 76 cases with therapy related leukaemia and myelodysplastic syndrome, Cancer Genetic and cytogenetics, 43, 227–241.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard, J., Pedersen, M., Roulston, D. and Philip, P. (1995). Different genetic pathways in leukaemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukaemia, Blood, 86, 3542–3552.
   PubMed Web of Science ®Google Scholar
• Traweek, S. T., Slovak, M. L., Nademanee, A. P., Brynes, R. K., Niland, J. C. and Forman, S. J. (1994). Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma, Blood, 84, 957–963.
   PubMed Web of Science ®Google Scholar
• Stone, R. M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinowe, S. N., Aster, J. C., Leavitt, P., Mauch, P., Freedman, A. S. et al. (1994). Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma, Journal of Clinical Oncology, 12, 2535–2542.
   PubMed Web of Science ®Google Scholar
• Thangaveleu, M., Bitter, M. A., Larson, R. A. et al. (1989). der(5) t(5;7) (q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders, Cancer genetics Cytogenetics, 32, 1–10.
   Google Scholar
• Van den Berghe, H., Mecucci, C., Delannoy, A. et al. (1990). Deletion of 5q by t(5;17) in therapy related myelodysplastic syndrome, Cancer genetics Cytogenetics, 48, 49–52.
   PubMedGoogle Scholar
• Scheres, J. M. J. C., Hustinx, T. W. S., Geraedts, J. P. M. et al. (1985). Translocation 1;7 in haematological disorders. A brief review of 22 cases, Cancer genetics Cytogenetics, 18, 207–213.
   PubMed Web of Science ®Google Scholar
• Wlodarska, I., Mecucci, C., Marynen, P. et al. (1995). TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12) (q33;p13) translocation or its variant t(10;12) (q24;p13), Blood, 85, 2848–2852.
   PubMed Web of Science ®Google Scholar
• Soekarman, D., Von Lindern, M., Van der Plas, D. C., Selleri, L., Bartram, C. R. I., Martiat, P., Culligan, D., Padua, R. A., Hasre-Voogt, K. P., Hagemeijer, A. and Grosveld, G. (1992). Dek-Can rearrangement in translocation (6;9) (p23;q34), Leukaemia, 6, 489–494.
   PubMed Web of Science ®Google Scholar
• Cuneo, A., Kerim, S., Vandenberghe, E. et al. (1989). Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome and acute nonlymphocytic leukaemia suggests multipotent stem cell involvement, Cancer Genetics Cytogenetics, 42, 209–219.
   PubMedGoogle Scholar
• Fenaux, P., Preudhomme, C. and Estienne, M. H. (1990). De novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases, Leukaemia research, 14, 1053–1059.
   PubMed Web of Science ®Google Scholar
• Wong, K. F., Hayes, K. J., Leung, S. and Glassman, A. B. (1996). The relationship between age and karyotypic abnormalities in myelodysplastic syndromes, Cancer Genetics and Cytogenetics, 88, 80–82.
   PubMedGoogle Scholar
• Tuncer, M. A., Paglliuca, A., Hisconmez, S. et al. (1992). Primary myelodysplastic syndromes in children: the clinical experience in 33 cases, British Journal of Haematology, 82, 347–353.
   PubMed Web of Science ®Google Scholar
• Narayanan, M. N., Geary, C. G., Harrison, C. J., Cinkotai, K. I. and Lewis, M. J. (1993). Three cases of the myelodysplastic syndrome with pericentric inversion of chromosome 16, British Journal of Haematology, 85, 217–219.
   PubMed Web of Science ®Google Scholar
• Maserati, E., Casali, M., Pasquali, F. et al. (1992). Translocation (8;21) in two cases of refractory anaemia with excess blasts in transformation, Cancer genetics cytogenetics, 58, 76–78.
   PubMed Web of Science ®Google Scholar
• Taj, A. S., Ross, F. M., Vickers, M. et al. (1995). t(8;21) myelodysplasia, an early presentation of M2 AML, British Journal of Haematology, 89, 890–892.
   PubMed Web of Science ®Google Scholar
• Willman, C. L. (1997). Molecular biology of elderly AML and its relationship to myelodysplasia, Leukaemia Research, Vol. 21, Supp. 1, S35(316).
   Google Scholar
• Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I. M., Head, D. R., Appelbaum, F. R. and Willman, C. L. (1997). Acute myeloid leukaemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study, Blood, 89, 3323–3329.
   PubMed Web of Science ®Google Scholar
• Lawrence, H. J., Broudy, V. C., Magenis, R. E. et al. (1987). Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anaemias, Blood, 70, 1003–1005.
   PubMed Web of Science ®Google Scholar
• Kere, J., Ruutu, T. and Chapelle, A. (1987). Monosomy 7 in granulocytes and monocytes in myelodysplastic syndromes, New England Journal of Medicine, 316, 499–503.
   PubMed Web of Science ®Google Scholar
• Gerritsen, W. R., Donohue, J., Bauman, J., Jhanwar, S. C., Kernan, N. A. et al. (1992). Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization, Blood, 80, 217–224.
   PubMed Web of Science ®Google Scholar
• Nyulund, S. J., Verbeek, W., Larramendy, M. L., Ruutu, T., Heinonen, K., Hallman, H. and Knuutila, S. (1993). Cell lineage involvement in four patients with myelodysplastic syndrome and t(1;7) or trisomy 8 studied by simultaneous immunophentyping and fluorescence in sity hybridization, Cancer Genetics Cytogenetics, 70, 120–124.
   PubMedGoogle Scholar
• Gibbons, B., Lillington, D. M., Monard, S., Young, B. D., Cheung, K. L., Lister, T. A. and Kearney, L. (1994). Fluorescence in situ hybridisation studies to characterise complete and partial monosomy 7 in myeloid disorders. Genes, Chromosomes and Cancer, 10, 244–249.
   PubMed Web of Science ®Google Scholar
• Knuutila, S., Teerenhovi, L., Larramendy, M. L., Elonen, E., Franssila, K. O. et al. (1994). Cell lineage involvement of recurrent chromosomal abnormalities in haemotologic neoplasms. Genes, Chromosomes and Cancer, 10, 95–102.
   PubMed Web of Science ®Google Scholar
• Van Lorn, K., Hagemeijer, A., Smit, E., Hahlen, K., Groeneveld, K. and Lowenberg, B. (1995). Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and the lymphoid lineage, Leukaemia, 9, 1818–1821.
   PubMed Web of Science ®Google Scholar
• Baurmann, H., Cherif, D. and Berger, R. (1993). Interphase cytogenetics by fluorescent in sity hybridization (FISH) for characterization on monosomy-7 associated myeloid disorders, Leukaemia, 7, 384–391.
   PubMed Web of Science ®Google Scholar
• Bernell, P., Jacobsson, B., Nordgren, A. and Hast, R. (1996). Clonal cell lineage involvement in myelodysplastic syndromes studies by in situ hybridization and morphology, Leukaemia, 10, 662–668.
   PubMed Web of Science ®Google Scholar
• White, N. J., Nacheva, E., Asimakopoulos, F. A., Bloxham, D., Paul, B. and Green, A. R. (1994). Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells, Blood, 83, 2809–2816.
   PubMed Web of Science ®Google Scholar
• Willemze, R., Stevens-Kroef, M. J. P. L., Kibbelaar, R. E. et al. (1997). Clonality of haematopoiesis in myelodysplasia. Leukaemia Research, Vol. 21, Supp. 1, S19(71).
   Google Scholar
• Lyon, M. (1972). X-chromosome inactivation and developmental patterns in mammals, Biological Reviews, 47, 1–35.
   PubMed Web of Science ®Google Scholar
• Prchal, J. T., Throckmorton, D. W., Carol, A. J. et al. (1978). A common progenitor for human myeloid and lymphoid cells, Nature, 274, 590–591.
   PubMed Web of Science ®Google Scholar
• Raskind, W. H., Triumali, N., Jacobsen, R. et al. (1984). Evidence for a multistep pathogenesis of a myelodysplastic syndrome, Blood, 63, 1318–1323.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., Fearon, E. R., Hamilton, S. R. and Feinberg, A. P. (1985). Use of restriction fragment length polymorphisms to determine the clonal origin of human tumours, Science, 227, 642–645.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., Fearon, E. R., Hamilton, S. R. et al. (1987). Clonal analysis using recombinant DNA probes from the X-chromosome, Cancer Research, 47, 4806–4813.
   PubMed Web of Science ®Google Scholar
• Fraser, N. J., Boyd, Y., Brownley, G. G. and Craig, I. W. (1987). Multi-allelic RFLP for M27B, an anonymous single copy genomic clone at Xp11.3-Xcen (HGM9 provisional No DXS255), Nucleic Acid Research, 15, 9616.
   PubMed Web of Science ®Google Scholar
• Abrahamson, G., Fraser, N. J., Boyd, Y. et al. (1990). A highly informative X-chromosome probe, M27B can be used for the determination of tumour clonality, British Journal of Haematology, 74, 371–372.
   PubMed Web of Science ®Google Scholar
• Allen, R. C., Zoghbi, H. Y., Moseley, A. B., Rosenblatt, H. M. and Belmont, J. W. (1992). Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X-chromosome inactivation, American Journal of Human Genetics, 51, 1229–1239.
   PubMed Web of Science ®Google Scholar
• Janssen, J. W. G., Busschle, M., Layton, M., Drexler, H. G., Lyons, J. et al. (1989). Clonal studies in the myelodysplastic: evidence of multipotent stem cell origin, Blood, 73, 248–254.
   PubMed Web of Science ®Google Scholar
• Tefferi, A., Thibodeau, S. N., Soldberg, L. A. et al. (1990). Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms, Blood, 75, 1770–1773.
   PubMed Web of Science ®Google Scholar
• Abrahamson, G., Boultwood, J., Madden, J. et al. (1991). Clonality of cell populations in refractory anaemia using the combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analysis, British Journal of Haematology, 79, 550–555.
   PubMed Web of Science ®Google Scholar
• Culligan, D. J., Cachia, P., Whittaker, J. et al. (1992). Clonal lymphocytes are detectable in only some cases of MDS, British Journal of Haematology, 81, 346–351.
   PubMed Web of Science ®Google Scholar
• Van Kamp, H., Fibbe, W. E., Rumo, P. M. et al. (1992). Clonal involvement of grnulocytes and monocytes, but not T and B lymphocytes and natural killer cells in patients with myelodysplasia: Analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene, Blood, 80, 1774–1780.
   PubMed Web of Science ®Google Scholar
• Tsukamoto, N., Morita, K., Maehara, T. et al. (1993). Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms, British Journal of Haematology, 83, 589–594.
   PubMed Web of Science ®Google Scholar
• Gilliland, D. G., Blanchard, K. L., Levy, J. et al. (1991). Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction, Proceedings of The National Academy of Science USA, Vol. 88, 6848–6852.
   PubMed Web of Science ®Google Scholar
• Anan, K., Ito, M., Misawa, M., Ohe, Y., Kai, S., Kohsaki, M. and Hara, H. (1995). Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMRA) gene, British Journal of Haematology, 89, 838–844.
   PubMed Web of Science ®Google Scholar
• Gale, R. E., Mein, C. A. and Lindt, D. C. (1996). Quantification of X-choromosome inactivation patterns in haematological samples using the DNAPCR-based HUMARA assay, Leukaemia, 10, 362–367.
   PubMed Web of Science ®Google Scholar
• Gale, R. E., Wheadon, H. and Lich, D. C. (1991). X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post chemotherapy females, British Journal of Haematology, 79, 193–197.
   PubMed Web of Science ®Google Scholar
• Gale, R. E., Wheadon, H., Boulos, P. and Linch, D. C. (1994). Tissue specificity of X-chromosome inactivation patterns, Blood, 83, 2899–2905.
   PubMed Web of Science ®Google Scholar
• Cachia, P. G., Culligan, D. J., Thomas, E. D. et al. (1992). Methylation of the DXS255 hypervariable locus 5′ CCGG site may be affected by factors other than the X-chromosome activation status, Genomics, 14, 70–74.
   PubMed Web of Science ®Google Scholar
• Gale, R. E. and Linch, D. C. (1993). Investigation of methylation at Hha I sites using the hypervariable probe M27 beta allows improved clonal analysis in myeloid leukaemia and demonstrates differences in methylation between leukaemic and remission samples, Leukaemia, 8, 190–194.
   Web of Science ®Google Scholar
• Bonnet, D. and Dick, J. E. (1997). Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nature Medicine, 3, 730–737.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj, S., Broxmeyer, H. E., Spitzer, G., Le-Maistre, A., Hultman, S., Ventura, G., Tigaud, J. D., Cork, M. A., Trujillo, J. M., Gutterman, J. U. and Hittlemann, W. N. (1989). Stimulation of non-clonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human GMCSF in a patient with therapy related myelodysplastic syndrome, Blood, 74, 1491–1498.
   PubMed Web of Science ®Google Scholar
• Anastasi, J., Feng, J., Le Beau, M. M., Larson, R. A., Rowley, J. D. and Vardiman, J. W. (1993). Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in sity hybridisation: lineage response to growth factor therapy and clone expansion, Blood, 81, 1580–1585.
   PubMed Web of Science ®Google Scholar
• Ito, T., Ohashi, H., Kagami, Y., Ichikawa, A., Saito, H. and Hotta, T. (1994). Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy, Leukaemia, 8, 839.
   PubMed Web of Science ®Google Scholar
• Asano, H., Ohashi, H., Ichihara, M., Kinoshita, T., Murate, T., Kobayashi, M., Saito, H. and Hotta, T. (1994). Evidence for non-clonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes, Blood, 84, 588–594.
   PubMed Web of Science ®Google Scholar
• Culligan, D. J., Bowen, D. T., May, A., White, D., Padua, R. A. and Burnett, A. K. (1995). Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression, British Journal of Haematology, 89, 675–677.
   PubMed Web of Science ®Google Scholar
• Delforge, M., Demuynck, Vandenberghe, P., Verhoef, G., Zachee, P., Van Duppen, V., Marijen, P., Van den Berghe, H. and Boogaerts, M. A. (1995). Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes, Blood, 86, 3660–3667.
   PubMed Web of Science ®Google Scholar
• Cachia, P. G., Culligan, D., Clark, R. E., Whittaker, J. A., Jacobs, A. and Padua, R. A. (1993). Clonal haemopoiesis following cytotoxic therapy for lymphoma, Leukaemia, 7, 795–800.
   PubMed Web of Science ®Google Scholar
• Fialkow, P. J., Singer, J. W., Raskind, W. H. et al. (1987). Clonal development, stem cell differentiation, and clinical remissions in acute non-lymphocytic leukaemias, New England Journal of Medicine, 317, 468–473.
   PubMed Web of Science ®Google Scholar
• Fialkow, P. J., Janssen, W. G. and Bartram, C. R. (1991). Clonal remissions in acute non-lymphocytic leukaemia: Evidence for a multistep pathogenesis of malignancy, Blood, 77, 1415–1417.
   PubMed Web of Science ®Google Scholar
• Gale, R. E., Wheadon, H., Goldstone, A. H. et al. (1993). Frequency of clonal remissions in acute myeloid leukaemia, Lancet, 341, 138–142.
   PubMed Web of Science ®Google Scholar
• Jowitt, S. N., Liu Yin, J. A., Saunders, M. J. and Lucas, G. S. (1993). Clonal remissions in acute myeloid leukaemia are commonly associated with features of trilineage myelodysplasia during remission, British Journal of Haematology, 85, 698–705.
   PubMed Web of Science ®Google Scholar
• Nash, R., Storb, R. and Neiman, P. (1988). Polyclonal reconstitution of human marrow after allogeneic bone marrow transplantation, Blood, 72, 2031.
   PubMed Web of Science ®Google Scholar
• Turham, A. G., Humphries, R. K., Phillips, G. L. et al. (1989). Clonal hematopoiesis demonstrated by X-linked DNA polymorphisms after allogeneic bone marrow transplantation, New England Journal of Medicine, 318, 76–81.
   Google Scholar
• Carter, G., Hughes, D. C., Clark, R. E. et al. (1990) RAS mutations in patients following cytotoxic therapy for lymphoma, Oncogene, 5, 411–416.
   PubMed Web of Science ®Google Scholar
• Cachia, P. G., Taylor, C., Thompson, P. W., Tennant, G. B., Masters, G., Pettersson, T., Whittaker, J. A., Burnett, A. K., Jacobs, A. and Padua, R. A. (1994). Non-dysplastic myelodysplasia?, Leukaemia, 8, 677–681.
   PubMed Web of Science ®Google Scholar
• Gale, R. E., Bunch, C., Moir, D. J., Patterson, K. G., Goldstone, A. H. and Linch, D. C. (1996). Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns, British Journal of Haematology, 93, 53–58.
   PubMed Web of Science ®Google Scholar
• Bartram, C. R. (1992). Molecular genetic aspects of myelodysplastic syndromes. In: Koeffler HP (Guest Ed.), Haematology/Oncology Clinics of North America: Myelodysplastic Syndromes, 6, 557–570.
   Google Scholar
• Gallagher, A., Darley, R. L. and Padua, R. (1997). The molecular basis of myelodysplastic syndromes, Haematologica, 82, 191–204.
   PubMed Web of Science ®Google Scholar
• Parker, J. and Mufti, G. J. (1996). RAS and myelodysplasia: lessons from the last decade. (Review), Seminars in Hematology, 33, 206–224.
   PubMed Web of Science ®Google Scholar
• Liu, E., Hjelle, B., Morgan, R. et al. (1987). Mutations of the kirsten ras proto-oncogene in human preleukaemia, Nature, 330, 186–188.
   PubMed Web of Science ®Google Scholar
• Padua, R. A., Carter, G., Hughes, D. et al. (1988). RAS mutations in myelodysplasia detected by oligonucleotide hybridisation and transformation, Leukaemia, 2, 503–510.
   PubMed Web of Science ®Google Scholar
• Lyons, J., Janssen, J. W. G., Bartram, C. et al. (1988). Mutations of Ki ras and N ras oncogenes in myelodysplastic syndromes, Blood, 71, 1707–1712.
   PubMed Web of Science ®Google Scholar
• Bar-Eli, M., Ahuja, H., Gonzalez-Cadavid, N. et al. (1989). Analysis of NRAS exon 1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing, Blood, 73, 281–283.
   PubMed Web of Science ®Google Scholar
• Yunis, J. J., Boot, A. J. M., Mayer, M. G. et al. (1989). Mechanisms of ras mutations in myelodysplastic syndrome, Oncogen., 4, 609–614.
   PubMed Web of Science ®Google Scholar
• Melani, C., Haliassos, A., Chomel, J. C. et al. (1990). Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease, British Journal of Haematology, 74, 408–413.
   PubMed Web of Science ®Google Scholar
• Van Kamp, H., de Piper, C., Verlaan-de Vries, M. et al. (1992). Longitudinal analysis of point mutations of the N-RAS proto-oncogene in patients with myelodysplasia using archived blood smears, Blood, 79, 1266–1270.
   PubMed Web of Science ®Google Scholar
• Farr, C. J., Saiki, R. K., Erlich, H. A. et al. (1988). Analysis of RAS gene mutations in acute myeloid leukaemia by polymerase chain reaction and oligonucleotide probes, Proceedings of the National Academy of Sciences USA, Vol. 85, 1629–1633.
   PubMed Web of Science ®Google Scholar
• Darley, R. L., Hoy, T. G., Baines, P., Padua, R. A. and Burnett, A. K. (1997). Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells, Journal of Experimental Medicine, 185, 1337–1347.
   PubMed Web of Science ®Google Scholar
• Gallagher, A., Padua, R. A., Al-Sabah, A., Hoy, T., Burnett, A. K. and Darley, R. L. (1995). Aberrant expression of p21RRAS but not p120GAP is a common feature of myelodysplasia, Leukaemia, 9, 1833–1840.
   PubMed Web of Science ®Google Scholar
• Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T. and Shannon, K. (1996). Loss of NFl results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells, Nature Genetics, 12, 144–148.
   PubMed Web of Science ®Google Scholar
• Miles, D. K., Freedman, M. H., Stephens, K., Pallavicini, M., Sievers, E. L., Weaver, M., Grunberger, T., Thompson, P. and Shannon, K. M. (1996). Patterns of haematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders, Blood, 88, 4314–4320.
   PubMed Web of Science ®Google Scholar
• Ludwig, L., Janssen, J. W., Schultz, A. S. and Bartram, C. R. (1993). Mutations within the FLR exon of NFl are rare in myelodysplastic syndromes and acute myeloblastic leukaemia, Leukaemia, 7, 1058–1060.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Vachee, A., Quesnel, B., Wattel, E., Cosson, A. and Fenaux, P. (1993). Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NFl) gene in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), Leukaemia, 7, 1071.
   PubMed Web of Science ®Google Scholar
• Quesnel, B., Preudhomme, C., Vanrumbeke, M., Vachee, A., Lai, J. L. and Fenaux, P. (1994). Absence of rearrangement of the neurofibrosis 1 (NFl) gene in myelodysplastic syndromes and acute myeloid leukaemia, Leukaemia, 8, 878–880.
   PubMed Web of Science ®Google Scholar
• Kaneko, H., Horiike, S., Nakai, H., Ueda, Y. et al., (1995). Neurofibromatosis 1 gene (NFl) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression, International Journal of Haematology, 61, 113–116.
   PubMed Web of Science ®Google Scholar
• Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M. and Shannon, K. (1997). Homozygous inactivation of the NFl gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders, New England Journal of Medicine, 336, 1713–1720.
   PubMed Web of Science ®Google Scholar
• Maris, J. M., Wiersma, S. R., Mahgoub, N., Thompson, P., Geyer, R. J., Hurwitz, C. G., Lange, B. J. and Shannon, K. M. (1997). Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1, Cancer, 79, 1438–1446.
   PubMed Web of Science ®Google Scholar
• Luna-Fineman, S., Shannon, K. M. and Lange, B. J. (1995). Chilhood monosomy 7: epidemiology, biology, and mechanistic implications, Blood, 85, 1985–1999.
   PubMed Web of Science ®Google Scholar
• Shannon, K. (1997). Molecular genetics of myeloid disorders characterized by—7/del(7q), Leukaemia Research, Vol. 21, Supp. 1, S35(135).
   Google Scholar
• Stephenson, J., Lizhen, H. and Mufti, G. J. (1995). Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes, Leukaemia Research, 19, 741–748.
   PubMed Web of Science ®Google Scholar
• Paquette, R. L., Landaw, E. M., Pierre, R. V., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F. and Koeffler, H. P. (1993). N-ras mutations are associated with poor prognosis and increased risk of leukaemia in myelodysplastic syndrome, Blood, 82, 590–599.
   PubMed Web of Science ®Google Scholar
• Padua, R. A., Darley, R., McGlynn, H. et al. (1997). Mutant RAS or FMS confer abnormal growth in haematopoietic cells: poor clinical outcome in myelodysplasia with RAS, FMS, and p53 mutations, Leukaemia Research, Vol. 21, Supp. 1, S36(138).
   PubMedGoogle Scholar
• Jonveaux, P. H., Fenaux, P., Quiquandon, I. et al. (1991). Mutations in the p52 gene in myelodysplastic syndromes, Oncogene, 6, 2243–2247.
   PubMed Web of Science ®Google Scholar
• Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in haematological malignancies, Blood, 84, 3148–3157.
   PubMed Web of Science ®Google Scholar
• Hawkins, J. M., Moorman, A. V., Hoffbrand, A. V., Martineau, M., Wright, F. S., Mehta, A. B., Prentice, H. G. and Seeker-Walker, L. M. (1994). Association of 17p loss with late stage of refractory disease in haematologic malignancy, Cancer, genetics, Cytogenetics, 77, 134–143.
   PubMed Web of Science ®Google Scholar
• Adamson, D. J., Dawson, A. A., Bennett, B., King, D. J. and Haites, N. E. (1995). p53 mutation in the myelodysplastic syndromes, British Journal of Haematology, 89, 61–66.
   PubMed Web of Science ®Google Scholar
• Mori, N., Hidai, H., Yokota, J., Okada, M., Motoji, T., Oshimi, K. and Mizoguchi, H. (1995). Mutations of the p53 gene in myelodysplastic syndrome and overt leukaemia, Leukaemia Research, 19, 869–875.
   PubMed Web of Science ®Google Scholar
• Lepelley, P., Soenen, V., Preudhomme, C., Meriat, A., Cosson, A. and Fenaux, P. (1995). bcl-2 expression in myelodysplastic syndromes and its correlation with haematological features, p53 mutations and prognosis, Leukaemia, 9, 726–730.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Quesnel, B., Vachee, A., Lepelley, P., Collyn-D'Hooghe, M., Wattel, E. and Fenaux, P. (1993). Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes, Leukaemia, 8, 1291–1293.
   Google Scholar
• Ridge, S. A., Worwood, M., Oscier, D. et al. (1990). FMS mutations in myelodysplastic, leukaemic and normal subjects, Proceedings of The National Academy of Science USA, Vol. 87, 1377–1380.
   PubMed Web of Science ®Google Scholar
• Tobal, K., Pagliuca, A., Bhatt, B. et al. (1990). Mutations of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukaemia, Leukaemia, 4, 486–489.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Vachee, A., Lepelley, P., Vanrumbeke, M., Zandecki, M., Quesnel, B., Cosson, A. and Fenaux, P. (1994). Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes, British Journal of Haematology, 87, 61–67.
   PubMed Web of Science ®Google Scholar
• Bowen, D. T., Padua, R. A., Burnett, A. K., deCastro, C. M. and Kaufman, R. E. (1993). Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots, Leukaemia, 7, 1883–1885.
   PubMed Web of Science ®Google Scholar
• Stephenson, J., Czepulkowski, B., Hirst, W. and Mufti, G. J. (1996). Deletion of the achetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), Leukaemia Research, 20, 235–241.
   PubMed Web of Science ®Google Scholar
• Dreffus, F., Bouscary, D., Melle, J., Ribrag, V., Guesnu, M. and Varet, B. (1995). Expression of the Evi-1 gene in myelodysplastic syndromes, Leukaemia, 9, 203–205.
   PubMed Web of Science ®Google Scholar
• Ohyashiki, J. H., Ohyashiki, K., Shimamoto, T., Kawakubo, K., Fujimura, T., Nakazawa, S. and Toyama, K. (1995). Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukaemia: possible association with GATA-1, GATA-2, and stem cell leukaemia expression, Blood, 85, 3713–3718.
   PubMed Web of Science ®Google Scholar
• Backx, B., Broederss, L., Hoefsloot, L. H., Wognum, B. and Lowenberg, B. (1996). Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand, Leukaemia, 10, 466–472.
   PubMed Web of Science ®Google Scholar
• Wlodarska, I., Mecucci, C., Marynen, P., Gou, C., Franckx, D. el al. (1995). TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;913), Blood, 85, 2848–2852.
   PubMed Web of Science ®Google Scholar
• Hoglund, M., Johansson, B., Pedersen-Bjergaard, J., Marynen, P. and Mitelman, F. (1996). Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2, Blood, 87, 324–330.
   PubMed Web of Science ®Google Scholar
• Raynaud, S. D., Baens, M., Grosgeorge, J., Rodgers, K. et al. (1996). Fluorescence in situ hybridization analysis of t(3;12)(q26;p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes, Blood, pp. 682–689.
   Google Scholar
• The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukaemia produces a novel fusion gene, NPM-MLF1, Oncogene, 12, 265–275.
   PubMed Web of Science ®Google Scholar
• Tasak, T., Lee, S., Spira, S., Takeuchi, S., Hatta, Y., Nagai, M., Takahara, J. and Koeffler, H. P. (1996). Infrequent microsatellite instability during the evolution of myelodysplastic syndrome to acute myelocytic leukaemia, Leukaemia Research, 20, 113–117.
   PubMed Web of Science ®Google Scholar
• Kaneko, H., Horiike, S., Inazawa, J., Nakai, H. and Misawa (1995). Microsatellite instability is an early genetic event in myelodysplastic syndrome, Blood, 86, 1236–1237 (letter).
   PubMed Web of Science ®Google Scholar
• Counter, C. M., Gupta, J., Harley, C. B., Leber, B. and Bacchetti, S. (1995). Telomerase activity in normal leukocytes in hematologic malignancies, Blood, 85, 2315–2320.
   PubMed Web of Science ®Google Scholar
• Ohyashiki, K., Ohyashiki, J. H., Yahata, N. and Toyama, K. (1997). Detection of telomerase activity in cells in myelodysplastic syndromes: Application of in situ telomeric repeat amplification protocol (TRAP), Leukaemia Research, Vol. 21, Supp. 1, S37(144).
   Google Scholar
• Wynn, R. F., Cross, M. A., Hatton, C., Will, A. M., Lashford, L. S., Dexter, T. M. and Testa, N. G. (1998). Accelerated telomere shortening in young recipients of allogeneic bone marrow transplant, Lancet, 351, 178–181.
   PubMed Web of Science ®Google Scholar
• Shay, J. W. (1998). Accelerated telomere shortening in bone marrow recipients (commentary). Lancet, 351, 153–154.
   PubMed Web of Science ®Google Scholar
• Bowen, D. T. (1995). What is ineffective erythropoiesis in myelodysplastic syndromes?, Leukaemia and Lymphoma, 18, 243–247.
   PubMed Web of Science ®Google Scholar
• Clark, D. M. and Lampert, I. A. (1990). Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis, Leukaemia Lymphoma, 2, 415.
   PubMed Web of Science ®Google Scholar
• Razza, A., Gezer, S., Mundie, S., Gao, X.-Z., Alvi, S., Borok, R. et al. (1995). Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes, Blood, 86, 268–276.
   PubMed Web of Science ®Google Scholar
• Raza, A., Mundle, S., Iftikhar, A., Gregory, S., Marcus, B., Khan, Z. et al. (1995). Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastic reveals extensive apoptosis as the probable basis for ineffective hematopoiesis, American Journal of Haematology, 48, 143–154.
   PubMed Web of Science ®Google Scholar
• Raza, A., Mundle, S., Shetty, V., Chopra, H., Span, L. et al. (1996). Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines, International Journal of Haematology, 63, 265–278.
   PubMed Web of Science ®Google Scholar
• Shetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J. et al. (1996). Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes, Leukaemia Research, 20, 891–900.
   PubMed Web of Science ®Google Scholar
• Lepelley, P., Campergue, L., Grardel, N., Preudhomme, C., Cosson, A. and Fenaux, P. (1996). Is apoptosis a massive process in myelodysplastic syndromes?, British Journal of Haematology, 95, 368–371.
   PubMed Web of Science ®Google Scholar
• Bogdanovic, A. D., Trpinac, D. P., Jankovic, G. M., Bumbasirevic, V. Z., Obradovic, M. and Colovic, M. D. (1997). Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment, Leukaemia, 11, 656–659.
   PubMed Web of Science ®Google Scholar
• Rajapaksa, R., Ginzton, N., Rott, L. S. and Greenberg, P. L. (1996). Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells, Blood, 88, 4275–4287.
   PubMed Web of Science ®Google Scholar
• Peddie, C. M., Wolf, R., McLellan, L. I. Collins, A. R. and Bowen, D. T. (1997). Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration, British Journal of Haematology, 99, 625–631.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg, E., Kanter-Lewensohn and Ost, A. (1997). Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin, Leukaemia Research, 21, 415–425.
   PubMed Web of Science ®Google Scholar
• Bouscary, D., De Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F. and Fontenay-Roupie, M. (1997). Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes, Leukaemia, 11, 839–845.
   PubMed Web of Science ®Google Scholar
• DiGiuseppe, J. A., LeBeau, P., Augenbraun, J. and Borowitz, M. J. (1996). Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis, American Journal of Clinical Pathology, 106, 345–351.
   PubMed Web of Science ®Google Scholar
• Munker, R., Midis, G., Owen-Schaub, L. and Andreff, M. (1996). Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukaemias, myeloproliferative and myelodysplastic syndromes, Leukaemia, 10, 1531–1533.
   PubMed Web of Science ®Google Scholar
• Chui, D. H. K. and Clarke, B. J. (1982). Abnormal erythroid progenitor cells in human preleukaemia, Blood, 60, 362–367.
   PubMed Web of Science ®Google Scholar
• Amato, D. and Khan, N. R. (1983). Erythroid burst formation in cultures of bone marrow and peripheral blood from patients with refractory anaemia, Acta Haematologica, 70, 1–10.
   PubMed Web of Science ®Google Scholar
• Ruutu, T., Partanen, S., Lintula, R. et al. (1984). Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes, Scandinavian Journal of Haematology, 32, 395–402.
   PubMedGoogle Scholar
• Coutinho, L. H., Geary, C. G., Chang, J., Harrison, C. and Testa, N. G. (1990). Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndromes (MDS), British Journal of Haematology, 75, 16–25.
   PubMed Web of Science ®Google Scholar
• Glinsmann-Gibson, B., Spier, C., Baier, M., Taetle, R., Broudy, V. C. and List, A. F. (1994). Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndromes, 8, 827–832.
   Google Scholar
• Merchav, S., Nielsen, O. J., Rosenbaum, H., Sharon, R., Brenner, B., Tatarsky, I., Scigalla, P. and Wieczorek, L. (1990). In vitro studies of erythropoietindependent regulation of erythropoiesis in myelodysplastic syndromes, Leukaemia, 4, 771–774.
   PubMed Web of Science ®Google Scholar
• Milner, G. R., Testa, N. G., Geary, C. J. et al. (1977). Bone marrow culture studies in refractory cytopenia and smouldering leukaemia, British Journal of Haematology, 32, 251.
   Google Scholar
• Greenberg, P. L. (1986). In vitro culture techniques defining biological abnormalities in the myelodysplastic and myeloproliferative disorders, Clinical Haematology, 15, 973–993.
   PubMedGoogle Scholar
• Verma, D. S., Spitzer, G., Dicke, K. A. et al. (1979). In vitro agar culture patterns in preleukaemia and their clinical significance, Leukaemia Research, 3, 41.
   PubMed Web of Science ®Google Scholar
• Tennant, G. B. and Jacobs, A. (1988). Undetectable peripheral blood CFU-GM as a prognostic indicator in myelodysplastic syndrome, Leukaemia Research, 12, 961.
   PubMed Web of Science ®Google Scholar
• Tennant, G. B., Bowen, D. T. and Jacobs, A. (1991). Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high risk myelodysplasia, British Journal of Haematology, 77, 296.
   PubMed Web of Science ®Google Scholar
• Shipperus, M., Sonneveld, P., Lindemans, J. et al. (1990). The effects of interleukin-3, GM-CSF and G-CSF on the growth kinetics of colony forming cellls in myelodysplastic syndromes, Leukaemia, 4, 267–272.
   PubMed Web of Science ®Google Scholar
• Shipperus, M., Sonneveld, P., Lindemans, J. et al. (1990). The combined effects of IL-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells, Leukaemia Research, 14, 1019–1025.
   PubMed Web of Science ®Google Scholar
• Tennant, G. B., Al-Sabah, A. I., Culligan, D., Bowen, D. T. and Burnett, A. K. The prognostic significance of growth response of circulating myeloid progenitors to exogenous cytokines in three definable myelodysplastic sub-groups. Submitted for publication.
   Google Scholar
• Jacobs, A., Culligan, D. and Bowen, D. (1990). Erythropoietin and the myelodysplastic syndrome. In: Gurland, H. J. et al. (Eds.), Erythropoietin in renal and non renal anaemias.
   Google Scholar
• Jacobs, A., Janowska-Wieczorek, A. et al. (1989). Circulating erythropoietin in patients with myelodysplastic syndromes, British Journal of Haematology, 73, 36–39.
   PubMed Web of Science ®Google Scholar
• Bowen, D. T., Jacobs, A., Cotes, M. et al. (1989). Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes, European Journal of Haematology, 44, 30–32.
   Web of Science ®Google Scholar
• Bowen, D., Yancik, S., Bennet, L., Culligan, D. and Resser, K. (1993). Serum stem cell factor concentration in patients with myelodysplastic syndromes, British Journal of Haematology, 85, 63–66.
   PubMed Web of Science ®Google Scholar
• Zwierzina, H., Bammer, T., Rollinger-Holzinger, I., Herold, M., Fenaux, P., Nuessler, V., Hoflehner, E. and Geissler, D. (1996). In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels, Clinical Cancer Research, 2, 1031–1038.
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek, A., Belch, A. R., Jacobs, A. et al. (1991). Increased circulating colony stimulating factor 1 in patients with preleukaemia, leukaemia and lymphoid malignancies, 77, 1796–1803.
   Google Scholar
• Ogata, K., Tamura, S., Luo, E. et al. (1997). Plasma thrombopoietin (TPO) level in patients with myelodysplastic syndromes (MDS), Leukaemia Research, Vol.21, Suppl. 1, S25(94).
   Google Scholar
• Fountenay-Roupie, M., Lopez, I., Guerci, A., Lacombe, C., Botella, A. and Dreyfus, F. (1997). Serum levels of thrombopoietin (TPO) in myelodysplasias, Leukaemia Research, Vol. 21, Supp. 1, S25(95).
   Google Scholar
• Bynoe, A. G., Scott, C. S., Ford, P. and Roberts, B. E. (1983). Decreased T helper cells in myelodys- plastic syndromes, British Journal of Haematology, 54, 97–102.
   PubMed Web of Science ®Google Scholar
• Baumann, M. A., Milson, T. J., Patrick, C. W. et al. (1986). Immunoregulatory abnormalities in myelodysplastic disorders, American Journal Haematology, 22, 17–26.
   PubMed Web of Science ®Google Scholar
• Hockland, P., Kerndrup, G., Griffin, J. D. and Ellegaard, J. (1986). Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukaemia (refractory anaemia) patients using monoclonal antibodies, Blood, 67, 898–902.
   PubMed Web of Science ®Google Scholar
• Kerndrup, G., Meyer, K., Ellegaard, J. and Hockland, P. (1984). Natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukaemic syndrome, Leukaemia Research, 8, 239–247.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny, P., Desaint, B., Herrera, A. et al. (1984). Chronic myelomonocytic leukaemia according to the FAB classification. Analysis of 35 cases, Blood, 63, 634–638.
   PubMed Web of Science ®Google Scholar
• Economopoulos, T., Economidou, J., Giannopoulos, G. et al. (1995). Immune abnormalities in myelodysplastic syndromes, Journal of Clinical Pathology, 38, 908–911.
   Google Scholar
• Mufti, G. J., Figes, A., Hamblin, T. J. et al. (1986). Immunological abnormalities in myelodysplastic syndromes 1. Serum immunoglobulins and autoantibodies, British Journal of Haematology, 63, 143–147.
   PubMed Web of Science ®Google Scholar
• Okamoto, T., Okada, M., Takemoto, Y., Kanamuru, A. and Kakishita, E. (1997). Pathogenesis of immunological abnormalities in myelodysplastic syndromes, Blood, Vol. 90, Supp. 1, 520a, 2316.
   PubMedGoogle Scholar
• Green, A. R., Shuttleworth, D., Bowen, D. T. and Bentley, D. P. (1990). Cutaneous vasculitis in patients with myelodysplasia, British Journal of Haematology, 74, 364–365.
   PubMed Web of Science ®Google Scholar
• Pagliuca, A., Higgins, E., Samson, D. et al. (1990). Prodromal cutaneous vasculitis in myelodysplastic syndromes, British Journal of Haematology, 75, 444–446.
   PubMed Web of Science ®Google Scholar
• Savige, J. A., Smith, C., Chang, L. and Duggan, J. C. (1991). Anti-neutrophil cytoplasmic antibodies (ANCA) in a patient with the vasculitis of myelodysplasia, British Journal of Haematology, 78, 583–584.
   PubMed Web of Science ®Google Scholar
• Tichelli, A., Gratwohl, A., Nissen, C. et al. (1992). Morphology in patients with severe aplastic anaemia treated with antilymphocyte globulin, Blood, 80, 337–345.
   PubMed Web of Science ®Google Scholar
• Marsh, J. C. and Geary, C. G. (1991). Annotation: Is aplastic anaemia a pre-leukaemic disorder?, British Journal of Haematology, 77, 447.
   PubMed Web of Science ®Google Scholar
• De Planque, M. M., Bacigalupa, A., Wursch, A. et al. (1989). Long-term follow up of severe aplastic anaemia patients treated with antithymocyte globulin, British Journal of Haematology, 73, 121–126.
   PubMed Web of Science ®Google Scholar
• Moldrem, J. J., Caples, M., Mavroudis, D., Plante, M., Young, N. S. and Barrett, A. J. (1997). Antithymocyte globulin for patients with myelodysplastic syndrome, British Journal of Haematology, 99, 699–705.
   PubMed Web of Science ®Google Scholar
• Mufti, G. J., Hamblin, T. J., Clein, G. P. and Race, C. (1983). Coexistent myelodysplasia and plasma cell neoplasia, British Journal of haematology, 54, 91–96.
   PubMed Web of Science ®Google Scholar
• Copplestone, J. A., Mufti, G. J., Hamblin, T. J. and Oscier, D. G. (1986). Immunological abnormalities in myelodysplastic syndromes II. Coexistent lymphoid or plasma cell neoplasms, British Journal of Haematology, 63, 149–159.
   PubMed Web of Science ®Google Scholar
• Hamblin, T. J., Copplestone, J. A., Mufti, G. J. and Oscier, D. G. (1987). Coexisting lymphoid or plasma cell neoplasms, British Journal of haematology, 65, 376.
   PubMed Web of Science ®Google Scholar
• Hamblin, T. J. (1992). Immunological abnormalities in myelodysplastic syndromes. In: Koeffler, H. P. (Guest Ed.), Haematology/Oncology Clinics of North America, Vol. 6, 571–586.
   Google Scholar
• Kaczmarski, R. S. and Mufti, G. J. (1993). The pathophysiology and management of HIV-associated haematological abnormalities, Haematologica, 25, 1–17.
   Google Scholar